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Expression of topoisomerase II alpha and beta in an adenocarcinoma cell
line carrying amplified topoisomerase II alpha and retinoic acid receptor
alpha genes
J. Coutts, J.A. Plumb, R. Brown & W.N. Keith
CRC Department ofMedical Oncology, Beatson Laboratories, Alexander Stone Building, Garscube Estate, Bearsden, Glasgow,
G61 IBD, UK.
Summary Human topoisomerase II enzymes are targets for a number of widely used anticancer agents. We
have analysed a lung adenocarcinoma cell line CALU3, which has co-amplified topoisomerase IIax and ERBB2
sequences, for the structure of the amplicon and for expression of both topoisomerase Ila and P. The region of
chromosome 17q amplified in CALU3 also includes the retinoic acid receptor a locus and is therefore similar
to the amplicon observed in breast cancers carrying amplified topoisomerase IIa and retinoic acid receptor
sequences. The use of fluorescence in situ hybridisation localises the amplified topoisomerase Ila sequences to a
cluster on one chromosome with single copies localised to others. CALU3 expresses high levels of
topoisomerase Ila as determined by Western blot, immunofluorescence and enzyme activity. The enzyme
activity extracted from CALU3 is sensitive to inhibition by the topoisomerase II poison etoposide.
Topoisomerase Ip expression was observed in three lung cancer cell lines including CALU3 and was confined
to the nucleoli. Thus, the CALU3 cell line is an ideal model to study the amplification and expression of
topoisomerase Ila in adenocarcinomas.
Topoisomerase II enzymes localised in the nucleus catalyse
the breakage and rejoining of DNA (Takano et al., 1992).
The enzyme cuts a gate in the DNA through which a second
molecule of DNA can pass. This DNA manipulation is vital
to a number of cellular processes such as chromosome con-
densation, replication and segregation as well as gene trans-
cription and topoisomerase II activity is associated with all
these processes (Anderson & Roberge, 1992).
Topoisomerase II activity in human cells can be attributed
to the expression of two distinct genes. Topoisomerase II
alpha is localised to chromosome 17q bands 21-22 (Tsai-
Pflugfelder et al., 1988) whereas topoisomerase II beta is
localised to chromosome 3p24 (Tan et al., 1992; Jenkins et
al., 1992). Both genes are functional but their products differ
in sequence and biochemical activity (Jenkins et al., 1992;
Drake et al., 1989). Expression of the topoisomerase II alpha
gene is cell cycle regulated in contrast to the relatively con-
stant expression of the beta gene product (Drake et al., 1989;
Woessner et al., 1991). Recent studies have also indicated
that the alpha and beta enzymes are sublocalised within the
nucleus to the nucleoplasm and nucleoli respectively (Negri et
al., 1992).
Interest in topoisomerase II is due both to its essential
catalytic activity in normal cells and that it is a key target for
a group of anticancer agents including etoposide, dox-
orubicin and mAMSA (Takano et al., 1992; Liu, 1989).
Topoisomerase II interactive drugs interfere with the normal
catalytic cycle of the enzyme resulting in cell death. The
quantity of topoisomerase II within a cell will determine its
sensitivity to topoisomerase inhibitors with high levels con-
ferring sensitivity to the cytotoxic effects of the drugs
(Takano et al., 1992). Indeed, one cell line selected for sen-
sitivity to doxorubicin has increased expression of
topoisomerase II compared to its parental line (Davies et al.,
1988). In addition, yeast cells which over express
topoisomerase II encoded by a plasmid are hypersensitive to
topoisomerase II inhibitors (Nitiss et al., 1992). In contrast,
cell lines selected for resistance to the cytotoxic actions of
topoisomerase inhibitors express low levels of topoisomerase
or produce a mutated protein with altered catalytic activity
(Takano et al., 1992). Due to the clinical use of
topoisomerase II inhibitors (Muggia & Gill, 1991) the levels
of expression in tumours may be important in determining
the success of the treatment. Molecular changes at
topoisomerase loci which result in altered expression are
therefore important and recently it has been shown that the
topoisomerase II alpha gene is co-amplified along with
ERBB2 in a subset of breast adenocarcinomas (Keith et al.,
1993).
We have previously shown that the lung adenocarcinoma
cell line CALU3, has co-amplification of ERBB2 and
topoisomerase Ilcc, (Keith et al., 1992). This cell line therefore
provides a model to examine the role of topoisomerase Ila
amplification and expression in drug sensitivity. We have
now investigated the expression, localisation and enzymatic
activity of both topoisomerase Ila and P in CALU3 and
further characterised the amplicon containing the
topoisomerase Ila gene. We show here that the amplified
topoisomerase II alpha gene in CALU3 is expressed at a high
level and that enzyme activity is inhibited by a topoisomerase
II interactive drug. Immunofluorescence studies using
antibodies against topoisomerase II alpha and beta show the
alpha product to be expressed heterogeneously within the cell
population. In contrast, the beta isoform is expressed in all
cells and localised to the nucleolus. In addition, we show by
fluorescence in situ hybridisation (FISH), that the
topoisomerase II alpha amplification in CALU3 is intrach-
romosomal and clustered in one region with single gene
copies also detectable on other chromosomes. In agreement
with the observations in breast cancer, the chromosome 17q
amplicon in CALU3 contains at least three genes, namely
ERBB2, topoisomerase IIa and RARa and is a good model
for studying molecular alterations around the topoisomerase
IIa locus in breast cancer and their effects on gene expres-
sion.
Materials and methods
Cell lines and cytotoxicity assays
The human non-small cell lung carcinoma cell lines CALU3
and SK-MES were obtained from the American Type Cul-
ture Collection (ATCC Rockville, MD). L-DAN is a
squamous lung cancer cell line established in our own
laboratory. Cells were grown in a mixture of Hams F10 and
Dulbecco's modified Eagles medium (50:50, Life Techno-
logies, Paisley, Scotland) supplemented with glutamine
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(2 mM) and foetal calf serum (10%). The three lines CALU3,
SK-MES and L-DAN, have ICs values for etoposide of
2.3 x 10-8M, 81-120 x 10-8 and 92-110 x 10-8M respec-
tively and IC5o values for doxorubicin of 2.7 x 10-9M,
48-53 x 10-9M and 34-70 x 10-9M respectively (Merry et
al., 1987). Confirmation of the sensitivity of CALU3 to
topoisomerase II inhibitory drugs was determined by a tetra-
zolium dye based microtitration assay as described previously
(Plumb et al., 1989).
Topoisomerase II alphaprobe andprobe labelling
The topoisomerase II alpha probe used for in situ hybridisa-
tion was a 35 kilobase cosmid (Hochhauser et al., 1992)
kindly provided by Dr Ian Hickson, (ICRF, Oxford). Cos-
mid DNA was labelled with digoxigenin-ll-dUTP by nick
translation according to the manufacturer's instructions,
(Boehringer Mannheim). Labelled cosmid was precipitated in
the presence of a 50-fold excess of human COTI DNA and
resuspended in hybridisation buffer consisting of 50% for-
mamide, 2 x SSC (1 x SSC is 0.15 M NaCl, 0.015 M sodium
citrate pH 7), 500fgml-' salmon sperm DNA, 5% dextran
sulphate, at a concentration of 2 ng LI-'.
In situ hybridisation (Pinkel et al., 1986, Nederlofet al.,
1992)
Metaphase spreads were fixed in 3: 1 methanol, acetic acid
for 1 h and then treated with RNAse (1I00 tg ml-') for 1 h.
Slides were then fixed in 1% paraformaldehyde in PBS and
dehydrated. Chromosomes were denatured prior to hybrid-
isation in 70% formamide/2 x SSC at 70°C for 2 min and
dehydrated. Probe was denatured at 70°C for 5 min and
allowed to reanneal at 37°C for 1 h. Ten microlitres of probe
was applied to denatured chromosomes and hybridisation
was carried out under a sealed coverslip overnight in a
humidified chamber.
Probe detection
After hybridisation slides were washed twice in 50% for-
mamide, 1 x SSC, 42°C, 10 min, followed by two washes in
2 x SSC 42°C, 10 min each. Prior to immunocytochemical
detection, slides were incubated with Boehringer Mannheim
blocking buffer, (0.5% blocking reagent in 0.1 M maleic acid,
0.15 MNaCl pH 7.5, 0.05% Tween 20), for 30 min at 37°C.
The first antibody was anti-digoxigenin raised in sheep (Boe-
hringer Mannheim), 1 pig ml-', in the above buffer, 37°C, 1 h.
Slides were washed for 20 min in 0.1 M maleic acid,
0.15 M NaCl, 0.05% Tween 20, pH 7.5. The second antibody,
FITC-conjugated donkey anti-sheep (Jackson ImmunoRe-
search), diluted in the above blocking buffer at 3ligml1l was
applied to slides for 30 min, 37°C. Slides were then washed
for 30 min, counterstained with propidium iodide (0.4 yg
ml-') and mounted in anti-fade medium (Vectashield, Vector
Labs). Fluorescence was analysed on a Bio-Rad MRC-600
laser scanning confocal microscope equipped with a krypton/
argon ion laser using 488/568 nm line excitation and dual
channel 522 nm and 585 nm emission filters.
Immunofluorescence
Cells were cultured on multi-chamber slides at low cell den-
sity, rinsed in PBS and fixed in acetone for I min at room
temperature. Slides were blocked in 3% BSA in PBS, 0.05%
Tween 20 for 10 min prior to the addition of antibodies.
Polyclonal antiserum against topoisomerase II alpha was
obtained from TopoGen (Columbus Ohio), the monoclonal
antibody to topoisomerase II beta was kindly provided by Dr
G.C.B. Astaldi Ricotti (Negri et al., 1992). Both antibodies
were diluted 1:20 in 3% BSA in PBS, 0.05% Tween. Incub-
ations were for 2 h at room temperature. FITC-conjugated
donkey anti-rabbit and FITC-conjugated sheep anti-mouse
antibodies (Jackson Immunoresearch), at 30tgml1' in 3%
BSA, PBS, 0.05% Tween 20, were applied for 30 min at
room temperature to detect the polyclonal alpha antiserum
and the monoclonal beta antibody respectively. Slides were
washed for 15 min in PBS, 0.05% Tween 20, counterstained,
mounted and analysed by confocal microscopy as described
above. In order to gain quantitative, comparative data, image
acquisition parameters were set and remained unaltered dur-
ing image collection by confocal microscopy. Pre-incubation
of the alpha polyclonal antiserum with its complimentary
peptide (TopoGen, Columbus Ohio) abolishes antigen bind-
ing and can be used to calibrate the image detection para-
meters.
Topoisomerase II assays
Topoisomerase activity was extracted from cell lines as des-
cribed by van der Zee et al. (1991). Topoisomerase II activity
was quantified using a kit obtained from TopoGen (Colum-
bus, Ohio). Decatenation assays were carried out according
to the manufacturer's instructions. Inhibition of topoiso-
merase II activity by etoposide was carried out by addition of
the drug to the decatenation assays in 2 l.t of DMSO, (final
concentration of DMSO is 2%, also added to controls).
Assay products were resolved by agarose gel electrophoresis
and stained with 0.5 ytg ml-' ethidium bromide. The gels
were then photographed and the negatives contact print-
ed.
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Figure 1 Southern blot analysis of DNA extracted from CALU3
cell line. Lane 1; DNA extracted from SK-MES-1. Lane 2; DNA
extracted from L-DAN. Lane 3: DNA extracted from CALU3.
All DNA samples were digested with PstI. a, Hybridisation to
topoisomerase II a, b, Hybridisation to RARa, c, Hybridisation
to PKCa, d, Hybridisation to immunoglobulin heavy chain
sequences to control for DNA loading.TOPO II AND RARa IN Calu3 795
Western blot analysis
Cell extracts containing topoisomerase II activity were
resolved on 6% polyacrylamide gels and transferred to
Immobilon-P membranes. To detect topoisomerase II alpha
by Western blot analysis a polyclonal antibody obtained
from Cambridge Research Biochemicals (Cheshire, UK) was
used as previously described (Keith et al., 1993). Densi-
tometry was performed using a Molecular Dynamics laser
scanning densitometer.
Southern blot analysis
Genomic DNA was isolated from cell lines as previously
described (Keith et al., 1992), and digested with restriction
enzymes according to the manufacturer's directories. Hybri-
disations were carried out as described previously (Keith et
al., 1992). The probe SPI was used to detect topoisomerase
IIa sequences (Chung et al., 1989), pHPKC-alpha 7 to detect
PKCcx (Parker et al., 1986), p63 to detect RARx and pHJi
was used as a control for DNA loading (Keith et al., 1992).
The RARo and PKCx probes were obtained from the
ATCC.
Results
Detection ofRARa and topoisomerase II a gene amplification
by Southern blot analysis
Previously, we have shown ERBB2 and topoisomerase IIa to
be co-amplified in CALU3 (Keith et al., 1992). We have now
expanded this analysis to a number of other chromosome
17q loci.
DNA extracted from CALU3 cell line was analysed for
amplifcation of genes on chromosome 17q. Figure 1 shows a
Southern blot of DNA extracted from the lung cancer cell
lines, SK-MES (lane 1); L-DAN (lane 2); CALU3 (lane 3).
The filter was sequentially hybridised to analyse the copy
number of (a) topoisomerase IME; (b) RARa; (c) Protein
kinase Co (PKCa); (d) pHJi loading control. The topoiso-
merase IIa and RARa loci have previously been localised to
chromosome 17q 21-22 (Tsai-Pflugfelder et al., 1988; Mattei
et al., 1988). The PKCa locus has been mapped to chromo-
some 17q 22-24, (Parker et al., 1986). Figure 1 shows that in
addition to the topoisomerase IIa locus the RARa locus is
amplified in CALU3. Hybridisation of the filter to detect
PKCa shows that the increased copy number of RARa and
topoisomerase IIa is not due to aneuploidy but to ampli-
fication, as CALU3 shows no evidence of increased copy
numbers of PKCo sequences. Densitometry of the auto-
radiographs in Figure 1 shows topoisomerase IIa and RARa
sequences to be amplified four fold in CALU3 compared to
the other lines.
Analysis oftopoisomerase II alpha amplification by
fluorescence in situ hybridisation (FISH)
In order to further characterise the nature of amplified topo-
isomerase Ila sequences in CALU3 we have used fluorescence
in situ hybridisation. As shown in Figure 2a, hybridisation of
the topoisomerase II alpha cosmid to chromosomes prepared
from control lymphocytes detects the two alleles as expected.
In the metaphase spread shown all four chromatids are
labelled. Figure 2b shows hybridisation of topoisomerase II
alpha to a metaphase spread prepared from CALU3. Fluore-
scent signal is observed on several chromosomes with a
cluster of signals localised to one chromosome suggesting
that the amplified sequences are intra-chromosomal. There
was no evidence for extra-chromosomal sequences. The pat-
tern of hybridisation was consistent between nuclei within the
cell line. Each nucleus had five copies of topoisomerase IIa,
three of which were clustered on one chromosome. Occas-
Figure 2 Detection of topoisomerase II alpha gene copies by FISH in a, metaphase chromosomes from normal lymphocytes and
b, metaphase chromosomes from CALU3 adenocarcinoma cell line. Chromsomes counterstained red, alpha gene hybridisation





Figure 3 Detection of topoisomerase alpha expression by
Western blot analysis. Lane 1, L-DAN. Lane 2, CALU3, Lane 3,
SK-MES. Fifty micrograms of protein were run per lane. Molec-
ular mass standards in kiloDaltons are shown to the right of the
autoradiograph.
sionally cells were found with seven regions of hybridisation
of which the two additional hybridisations may represent a
low level of hybridisation to telomeric repeat sequences. The
regions of hybridisation marked by arrows in Figure 2b
represent topoisomerase II alpha sequences in CALU3, the
remaining two regions of hybridisation are telomeric and due
to the complex karyotype of the cell line, cannot be unam-
biguously assigned as topoisomerase alpha as the probe
used contains repeat sequences which can hybridise to telo-
meric sequences. However, under the conditions of hybridisa-
tion used, the intensity of any telomeric hybridisation in
lymphocyte controls is much lower than the topoisomerase
Ilo signal (data not shown).
Analysis of topoisomerase II expression by Western blot and
immunofluorescence
The CALU3 cell line is relatively sensitive to topoisomerase
II inhibitory agents etoposide and doxorubicin when com-
pared 'to other lung cancer cell lines (see Materials and
methods, Merry et at., 1987; Carmichael et al., 1985: Giac-
cone et at., 1992). In order to investigate whether expression
of the amplified topoisomerase II alpha gene is responsible
for the sensitivity to topoisomerase inhibitors, expression of
the alpha and beta genes was examined by Western blot
analysis and immunofluorescence. For comparison with
CALU3, two other non-small cell lung cancer cell lines,
L-DAN and SK-MES, which do not have amplified topo-
isomerase II genes (Keith et al., 1992) were included in the
analysis. Figure 3 shows a Western blot of topoisomerase II
alpha expression in L-DAN (lane 1), CALU3 (lane 2) and
SK-MES (lane 3). From Figure 3 it can be seen that CALU3
expresses topoisomerase II alpha at higher levels than the
other cell lines. Densitometric analysis of the autoradio-
graphs shows CALU3 to express 10-15 times more topoiso-
merase II alpha than the other lines. Therefore amplification
of the topoisomerase II alpha gene in CALU3 is accom-
panied by high levels of expression.
The high levels of topoisomerase II alpha expression in
CALU3 was confirmed by immunofluorescence using a
second polyclonal antibody as described in the Materials and
methods. Figure 4a, c, and e, shows topoisomerase II alpha
expression in optical section of L-DAN, CALU3 and SK-
MES respectively. The nuclei are counterstained red with
propidium iodide and the topoisomerase II alpha expression
in CALU3, as visualised by the green fluorescence, is con-
fined to the nucleus as expected. In contrast to Western blot
analysis, immunofluorescent detection of the alpha protein in
CALU3 highlights the heterogeneity in alpha expression
between cells (Figure 4c). Topoisomerase II alpha expression
is known to be cell cycle regulated but whether the observed
heterogeneity in expression is due to this or sub-population
diversity is untested. The lower levels of topoisomerase II
alpha expression observed in L-DAN and SK-MES by
Western blot analysis were also confirmed by immunofluore-
scence. However, in order to maintain the optimal conditions
for visualisation of the alpha protein in CALU3, alpha ex-
pression in the other two lines shown in Figure 4a and e is
almost undetectable due to the settings for digital image
analysis used for this experiment (see Materials and
methods).
The topoisomerase II beta enzyme is also a target for
topoisomerase interactive drugs (Drake et al., 1989). We
therefore analysed the three cell lines for beta expression to
complete their topoisomerase II isoenzyme profiles. We were
unable to generate consistent results on beta expression by
Western blot analysis due to the instability of the protein
during extraction. The instability of the beta protein has been
reported on several occasions (Woessner et al., 1990; Negri et
al., 1992; Holden et al., 1992). However, there were no major
differences in the levels of the 150 kD protein between the
three cell lines. There is no information on how the P protein
degrades and so different cell lines may show varying stability
of the P protein. In order to circumvent this problem, beta
expression was analysed by immunofluorescence. Figure 4b,
d and f shows expression of topoisomerase II beta in L-
DAN, CALU3 and SK-MES respectively. Beta expression is
reported to be largely confined to the nucleolus (Negri et al.,
1992) and the data presented in Figure 4 confirms this. All
three lines express the beta isozyme and it is expressed in
every cell in the population. Immunocytochemistry is only
semi-quantitative and due to the intense localised fluo-
rescence pattern obtained when analysing expression of the
beta protein, differences in expression levels between the
three lines is difficult to assess. Figure 4e shows that using
the polyclonal antiserum against the alpha protein, low levels
of fluorescence can be detected in the nucleoli. Whether this
represents a weak cross-reactivity of this antiserum with the
beta protein or co-localisation of the alpha enzyme is not
known.
Biochemical analysis oftopoisomerase II activity
In order to determine whether the high levels of topoiso-
merase II alpha protein observed in CALU3 has enzyme
activity, decatenation assays were carried out. Topoisomerase
II activity can be measured due to its ability to monomerise
covalently linked kinetoplast DNA circles. Decatenation of
kinetoplast DNA requires both the DNA breakage and
strand passage activities of topoisomerase II. The decatena-
tion assay does not however distinguish between the alpha
and beta isoforms. Figure 5 shows that CALU3 has at least
eight-fold more topoisomerase IIactivity than the other twoTOPO II AND RARa IN Calu3 797
Figure 4 Detection of topoisomerase II alpha and beta expression by immunofluorescence a and b, L-DAN, c and d CALU3, e
and f SK-MES. Topoisomerase II alpha expression is shown in a, c and e. Topoisomerase II beta expression b, d and f. Nuclei and
nucleoli are counterstained red, topoisomerase II expression is green. Scale bar is 10 microns.
cell lines. L-DAN and SK-MES have almost equivalent topo-
isomerase II activities. The extracts used in the decatenation
assays shown in Figure 5 are the same as those used for the
Western analysis of topoisomerase II alpha expression shown
in Figure 3. The results of both analyses are in agreement
with each other and show CALU3 to express high levels of
topoisomerase II. Western blot analysis of the extracts used
in the biochemical analysis for beta expression detected de-
graded beta protein of 150 kD (data not shown). The 150 kD
breakdown product of the beta enzyme has been observed
previously and shown to be active in the biochemical assays
(Negri et al., 1992). Thus, some of the topoisomerase II
activity detected may be due to the Ji isoform.
The topoisomerase II activity in protein extracts from
CALU3 is largely due to alpha enzyme expression (Figures 3,
4 and 5). The alpha gene is amplified in CALU3 (Figures 1
and 2) and so it is possible that it might contain genetic
alterations rendering its protein insensitive to inhibition by
topoisomerase II interactive drugs (Takano et al., 1992). We
therefore examined the ability of the topoisomerase II inter-
active drug etoposide to inhibit topoisomerase II activity in
decatenation assays. Figure 6 shows that etoposide can
inhibit topoisomerase II activity in extracts from all three cell
lines, including CALU3. Due to the higher levels of topoiso-
merase II activity in CALU3, only 1.25jg of extract was
used per reaction in comparison to 2.5 jig for L-DAN and
SK-MES.
Discussion
The adenocarcinoma cell line CALU3 has the co-amplifica-
tion of topoisomerase II alpha and ERBB2 sequences charac-
teristic of a subset of breast adenocarcinomas (Keith et al.,
1992, 1993). We therefore examined CALU3 as a suitable
model for the study of expression of topoisomerase II alpha
from an amplified locus and its consequences for cellular




1 2 3 4 5 6 7 8
Figure 5 Decatentation of kinetoplast DNA by cellular extracts from a, L-DAN; b, CALU3; c, SK-MES. Serial dilutions of
cellular extracts were assayed for topoisomerase II activity. Lane 2, 2.5 jig; Lane 3, 1.25 jug; Lane 4, 0.625 fig; Lane 5, 0.312 jg;
Lane 6, 0.156 jig; Lane 7, 0.078 jig; Lane 8, 0.039 jg; Lane 1, 0 jig. In the absence of cellular extract, catenated kinetoplast DNA,
(k), remains in the well of the gel (Lane 1). Topoisomerase II activity decatenates kinetoplast DNA to monomer mini-circles
(m).
amplified topoisomerase II alpha gene in CALU3 is exp-
ressed at high levels as determined by both Western blot
analysis and immunofluorescence, (Figures 3 and 4). Two
distinct antibodies were used to examine alpha expression by
Western and immunofluorescence therefore confirming by
independent methods that the isoform detected is indeed the
alpha product. Neither of the other two cell lines tested had
such high levels of alpha expression (Figures 3 and 4).
CALU3 has five copies of the topoisomerase IIa gene (Figure
2b) yet a 10-15-fold increase in expression over the other
two cell lines. This suggests there may be further complexity
in the regulation of the topoisomerase IIa gene at the trans-
criptional or post-transcriptional level.
The human genome has the potential to express a second
topoisomerase II isozyme encoded by the topoisomerase II
beta gene. There is still a paucity of data on the beta enzyme
but since its cloning, recent chromosomal mapping and the
generation of monoclonal antibodies against it, progress
should now become more rapid (Jenkins et al., 1992; Negri et
al., 1992). It is known however that the beta enzyme is
expressed, sensitive to inhibition by topoisomerase II interac-
tive drugs and likely to be confined to the nucleolus (Jenkins
et al., 1992; Drake et al., 1989; Negri et al., 1992). Any
model system used to study topoisomerase II inhibitors
would therefore benefit from the analysis of both alpha and
beta expression. In contrast to the alpha locus in CALU3,
none of the three lung cancer cell lines used in this study
have gross chromosomal changes at the beta locus (Keith et
al., 1992). By immunofluorescence there is little detectable
difference in beta expression between the cell lines, with all
lines expressing the beta isozyme in every cell (Figure 4). The
localisation of the beta product to the nucleoli confirms the
data of Negri et al., 1992 and suggests a role for the beta
product in ribosomal gene expression or organisation (Kim
& Wang, 1989). The data presented in Figure 4 on beta
expression suggest that the beta product represents a target
for inhibition and may be a target for topoisomerase II
poisons in the absence of alpha isozyme expression.
In addition to the correlation between alpha gene amplifi-
cation in CALU3 and high levels of alpha expression, bio-
chemical assays for topoisomerase II activity confirmed a
concomitant elevated level of activity which could be inhib-
ited by etoposide (Figures 4 and 5). Taken together, the
Western blot analysis, immunofluorescence studies and the
enzyme activity assays suggest that the sensitivity of CALU3
to topoisomerase inhibitors (Merry et al., 1987) is due to an
amplified and over-expressed topoisomerase II alpha gene.
The finding that in CALU3, expression of an amplified
topoisomerase II alpha gene can confer relative sensitivity to
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Figure 6 Inhibition of topoisomerase II activity by etoposide.
Cell extracts from a, L-DAN; b, CALU3; c, SK-MES were
assayed for decatenation activity in the presence of increasing
concentrations of etoposide, Lane 1, no drug, no protein extract;
Lane 2, DMSO dilutant control; Lane 3, 10 JAm; Lane 4, 100 JAm;
Lane 5, 200gim. Lanes 2 to 5 in a and c were assays using 2.5 fig
protein, Lanes 2 to 5 in b was an assay using 1.25 jug of CALU3
extract. To the right of the figure the catenated kinetoplast DNA
(k) and the decatenated monomer mini-circles (in) are marked.
importance to tumours where topoisomerase II alpha gene
amplification has occurred, as these cases may benefit prefer-
entially from treatment with topoisomerase II inhibitors.
We have previously shown that the region of amplification
found in primary breast tumours encompasses at least three
loci including ERBB2, RARa and topoisomerase IIa. The
PKCa locus was found to be outside the region of amplifi-
cation showing that the increased copy number of the three
genes is due to amplification rather than aneuploidy (Keith et
al., 1993). We have also previously shown that the lung
adenocarcinoma cell line, CALU3, has co-amplification
ERBB2 and topoisomerase IIa (Keith et al., 1992). As part
of our efforts to characterise similarities between the genetic
events found around the topoisomerase IIa locus in breast
cancer biopsies and the CALU3 cell line, we have shown that
the RARa locus is also amplified in CALU3 (Figure 1). By
Southern analysis, topoisomerase Ila and RARa are ampli-
fied around 4-fold. The finding that the locus for PKCoa is
not within the amplicon, is again consistent with the observa-
tions in breast cancer (Keith et al., 1992) and demonstrates
that the increased copy number of ERBB2, RARa and topo-
isomerase IIa in CALU3 is not due to aneuploidy. The
RARx receptor regulates normal cellular proliferation and
differentiation through activation by retinoids, (Bollag &
Holdener, 1992) and can, when expressed as a fusion protein
in acute promyelocytic leukaemia act as an oncogene. (Clark-
son, 1991). Gebert et al. (1991) have shown the RARa gene
to be expressed at high levels in CALU3 and so CALU3 may
be a suitable model to study retinoids in cancer therapy,
(Bollag & Holdener, 1992).
The finding that topoisomerase II alpha can be amplified
and expressed in adenocarcinomas opens the question as to
whether there is intra-tumour heterogeneity in topoisomerase
Ila gene amplification and its consequences for the sensitivity
of subpopulations within the tumour to cytotoxic agents.
Fluorescence in situ hybridisation is an ideal approach to
study this heterogeneity. Indeed, it has recently been shown
by FISH that in breast cancer biopsies there is considerable
intra-tumour variation in ERBB2 copy number (Kallioniemi
et al., 1992). Our demonstration that amplification of topo-
isomerase II alpha can be studied by FISH (Figure 2), opens
up the possibility of examining the importance of topoiso-
merase gene amplification and allele imbalance at the single
cell level.
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